RxDoctor Payments Data

Shelly Ronayne, NP

Nurse Practitioner · Springfield, MONPI 1023388220

Payments from drug & device makers

$6,977in general payments, 2019–2025

Across 418 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$817
  • Abbott$669
  • Novo Nordisk$613
  • GSK$479
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$6,977100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,977 in reported general payments places this provider in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$58,937
Medicare patients
157
Services billed
1,726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban62$57,557
MounjaroTirzepatide51$56,704
FarxigaDapagliflozin Propanediol32$39,934
OzempicSemaglutide42$39,101
JardianceEmpagliflozin16$25,315
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$11,752
XareltoRivaroxaban13$9,100
ArexvyRsvpref3 Antigen/As01e/Pf22$6,033
Advair HfaFluticasone Propion/Salmeterol11$3,420
Desvenlafaxine Succinate ErDesvenlafaxine Succinate34$2,654
Atorvastatin Calcium417$2,644
Levothyroxine Sodium220$1,858
Gabapentin97$1,752
Potassium Chloride87$1,688
Duloxetine Hcl50$1,640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$424$57,55762 claims
Lilly USA, LLCMounjaro$1,061$56,70451 claims
AstraZenecaFarxiga$1,099$39,93432 claims
Novo NordiskOzempic$613$39,10142 claims
Boehringer IngelheimJardiance$817$25,31516 claims
GSKTrelegy Ellipta, Arexvy$479$17,78534 claims
Johnson & JohnsonXarelto$86$9,10013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →